Cargando…
ePS5.02 Effect of omalizumab on glucocorticoid use and lung function in the treatment of allergic bronchopulmonary aspergillosis in people with cystic fibrosis: a systematic review and meta-analysis
Autores principales: | Elborn, J.S., Jin, M., Douglass, J.A., Calhoun, W.J., Agarwal, R., Lazarewicz, S., Yan, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Cystic Fibrosis Society.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184782/ http://dx.doi.org/10.1016/S1569-1993(22)00320-4 |
Ejemplares similares
-
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
por: Ashkenazi, Moshe, et al.
Publicado: (2018) -
Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab
por: Collins, Jennifer, et al.
Publicado: (2012) -
Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis
por: Beam, Keith T., et al.
Publicado: (2015) -
Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018) -
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis [Erratum]
Publicado: (2018)